Report for Q1 2026
Filed with SSE · · 13 pages · Chinese
Youcare Pharmaceutical Group Co. Ltd. on 6ix
Earlier from Youcare Pharmaceutical
- Announcement on Opening a Raised Fund Account and Signing a Raised Fund Account Storage Supervision Agreement
- Announcement on Progress in the 2nd Judicial Auction of a Portion of Company Shares Held by the Controlling Shareholder
- Announcement on Voluntary Disclosure of Subsidiary’s YKYY025 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval from the National Medical Products Administration for the Indications for the Treatment and Prevention of Human Bronchovirus Infection by the YKYY018 Inhalation Aerosol of Subsidiary
Later from Youcare Pharmaceutical
- Announcement on Investment in Construction Project
- Announcement on Completing the Transfer Registration in Judicial Auction of Partial Shares Held by Controlling Shareholders
- Announcement on Unfreezing of Partial Shares Held by Controlling Shareholders
- Announcement on Voluntary Disclosure of Withdrawal of Drug Registration Application by a Subsidiary
- Announcement on Voluntary Disclosure of YKYY017 Aerosol Inhalation Formulation Receiving FDA Clinical Trial Approval for the Indication of Prophylaxis and Treatment of Coronavirus-Associated Respiratory Infections
Follow Youcare Pharmaceutical into a list and get an email when it puts out news.
Follow Youcare Pharmaceutical